Table 1.
Study population characteristics (n=579) of colorectal cancer patients enrolled in the ColoCare Study at the National Center for Tumor Diseases (NCT) and University of Heidelberg (HD), Heidelberg in Germany and the Huntsman Cancer Institute (HCI), Salt Lake City, Utah and the Fred Hutchinson Cancer Center (FHCC), Seattle, Washington in the USA between June 2007 and July 2019.
| N (%) | |
|---|---|
| Age, mean (SD) | 62 (13) |
| Sex | |
| Female | 230 (40) |
| Male | 349 (60) |
| Race | |
| White | 549 (95) |
| Non-White | 28 (5) |
| Ethnicity | |
| Non-Hispanic | 567 (98) |
| Hispanic | 12 (2) |
| Stage at diagnosis | |
| I | 101 (17) |
| II | 148 (26) |
| III | 214 (37) |
| IV | 114 (20) |
| Tumor site | |
| Colon | 301 (51) |
| Rectum | 289 (49) |
| Neoadjuvant treatment | |
| Yes | 185 (32) |
| No | 394 (68) |
| Physical activity (MET-hrs/wk) | |
| Active (<8.75 MET-hrs/wk) | 239 (41) |
| Inactive (≥8.75 MET-hrs/wk) | 340 (59) |
| Mean (SD) | 12.5 (16.4) |
| BMI (kg/m2) | |
| Normal weight (≥18.5 and <25 kg/m2) | 207 (36) |
| Overweight (≥25 and <30 kg/m2) | 218 (38) |
| Obese (≥30 kg/m2) | 154 (26) |
| Mean (SD) | 27.6 (5.87) |
| Smoking status | |
| Never smoker | 198 (34) |
| Former smoker | 206 (36) |
| Current smoker | 77 (13) |
| Regular NSAID/Aspirin use in the past month | |
| Yes | 237 (66) |
| No | 123 (34) |
Data were missing for n=2 (<1%) on race, n=2 (<1%) on stage at diagnosis, n=1 (<1%) on neoadjuvant treatment, n=98 (17%) on smoking status, n=219 (37%) on regular NSAID/Aspirin use. Abbreviations: BMI: body mass index; SD: standard deviation; kg: kilogram; m: meter; hrs/wk: hours per week